PLXP - PLx Pharma Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 553.09M
Enterprise Value 349.28M
Trailing P/E N/A
Forward P/E 1-2.25
PEG Ratio (5 yr expected) 1-0.03
Price/Sales (ttm)52.84
Price/Book (mrq)N/A
Enterprise Value/Revenue 349.05
Enterprise Value/EBITDA 6-4.14

Trading Information

Stock Price History

Beta (3Y Monthly) 6.28
52-Week Change 366.26%
S&P500 52-Week Change 30.90%
52 Week High 37.41
52 Week Low 31.00
50-Day Moving Average 36.18
200-Day Moving Average 35.58

Share Statistics

Avg Vol (3 month) 310.4k
Avg Vol (10 day) 34.33k
Shares Outstanding 58.87M
Float 7.36M
% Held by Insiders 11.90%
% Held by Institutions 124.33%
Shares Short (Jul 31, 2019) 4188.83k
Short Ratio (Jul 31, 2019) 415.27
Short % of Float (Jul 31, 2019) 42.63%
Short % of Shares Outstanding (Jul 31, 2019) 42.13%
Shares Short (prior month Jun 28, 2019) 4165.3k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 28/1
Last Split Date 3Apr 20, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,203.86%

Management Effectiveness

Return on Assets (ttm)-31.08%
Return on Equity (ttm)-566.34%

Income Statement

Revenue (ttm)1M
Revenue Per Share (ttm)0.12
Quarterly Revenue Growth (yoy)9.20%
Gross Profit (ttm)753.11k
EBITDA -11.89M
Net Income Avi to Common (ttm)-33.81M
Diluted EPS (ttm)-3.87
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)21.26M
Total Cash Per Share (mrq)2.35
Total Debt (mrq)6.7M
Total Debt/Equity (mrq)893.10
Current Ratio (mrq)3.53
Book Value Per Share (mrq)-1.50

Cash Flow Statement

Operating Cash Flow (ttm)-9.55M
Levered Free Cash Flow (ttm)-5.41M